Release date: 2015-11-18
The flu is the most common disease in our lives, and medical scientists have been studying these diseases for decades. However, we are often at a loss as to what is considered a familiar disease. Every year, there are tens of thousands of people who are unfortunately "in the middle of the flu season", and the flu vaccines that have been spent heavily on development are often reduced in effectiveness after several years of listing. Although we all know that this is due to the rapid variability of influenza viruses, scientists have not been able to find a good way to deal with this problem. Recently, Sanofi, the leader in the flu vaccine market, announced its own vaccine improvement program, hoping to change the status quo.
Olivier Charmeil, head of the Sanofi vaccine division, said at the World Vaccine Congress in Spain this week that the company will work with the University of Georgia to develop the new influenza vaccine Cobra. This vaccine will be able to protect a variety of influenza strains.
Traditional vaccine protection is highly time sensitive. It is generally the public health department that monitors the flu epidemic and predicts the most likely influenza strains in the coming year, and the company will develop influenza vaccines for prevention. This has also caused the vaccines vaccinated this year to be ineffective next year, in addition to making vaccine companies less flexible. Sanofi hopes to find the "soft ribs" shared by different viruses by finding a variety of viruses to be sequenced, so as to extend the vaccine's effective period.
This is not the original creation of Sanofi. Many biopharmaceutical companies have already come to the forefront. For example, this summer, FluGen spent $12 million to support its broad-spectrum influenza vaccine products into clinical phase I research. In August of this year, Johnson & Johnson launched a similar study with The Scripps Research Institute.
Although Sanofi is full of confidence in this research, John Shiver, vice president of corporate R&D, acknowledges that the development of a once-in-a-lifetime vaccine is still out of reach, and future developers will be committed to developing a variety of flu Vaccine of the virus strain.
The US government has recently shown strong interest in developing such vaccines. Its subsidiary, BARDA, has recommended a $38 million grant for the development of new influenza vaccines and improvements in the surveillance of influenza outbreaks.
Source: Bio Valley
Steroid hormones, also known as steroid hormones, are a class of tetracyclic aliphatic hydrocarbon compounds with a cyclopentane polyhydrophenanthrene nucleus. It has very important medical value. It has a clear role in maintaining life, regulating sexual function, body development, immune regulation, skin disease treatment and birth control.
Steroids include steroids (eg cholesterol, lanosterol, sitosterol, stigmasterol, ergosterol), bile acids and bile alcohols, steroid hormones (eg adrenal corticosteroids, androgens, estrogens),
Our company specializes in providing steroid series products, welcome to inquire and order
Steroids Oil,Steroid Powder,Steroids Injections,Steroid Powder And Oil
XI AN RHINE BIOLOGICAL TECHNOLOGY CO.,LTD , https://www.xianrhinebiotech.com